53.95
前日終値:
$54.34
開ける:
$53.87
24時間の取引高:
1.07M
Relative Volume:
0.45
時価総額:
$133.03B
収益:
$48.03B
当期純損益:
$6.06B
株価収益率:
21.60
EPS:
2.4983
ネットキャッシュフロー:
$9.91B
1週間 パフォーマンス:
-1.02%
1か月 パフォーマンス:
-0.97%
6か月 パフォーマンス:
-4.10%
1年 パフォーマンス:
+13.09%
Sanofi Adr Stock (SNY) Company Profile
SNY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
53.98 | 133.03B | 48.03B | 6.06B | 9.91B | 2.4983 |
![]()
LLY
Lilly Eli Co
|
811.82 | 719.11B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
ABBV
Abbvie Inc
|
204.15 | 359.93B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
154.80 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
![]()
NVO
Novo Nordisk Adr
|
68.36 | 301.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
NVS
Novartis Ag Adr
|
110.37 | 216.49B | 51.72B | 11.94B | 13.81B | 5.88 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-21 | 開始されました | Goldman | Neutral |
2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
2024-07-26 | 繰り返されました | Argus | Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-10-30 | ダウングレード | Stifel | Buy → Hold |
2023-09-06 | アップグレード | Berenberg | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
2022-12-13 | 再開されました | Morgan Stanley | Overweight |
2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
2022-08-09 | ダウングレード | UBS | Buy → Neutral |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 開始されました | Deutsche Bank | Sell |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
2020-03-11 | アップグレード | Goldman | Neutral → Buy |
2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 開始されました | Bernstein | Outperform |
2019-08-14 | アップグレード | UBS | Neutral → Buy |
2018-12-11 | アップグレード | Jefferies | Hold → Buy |
2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
2018-03-23 | アップグレード | Liberum | Hold → Buy |
2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
FDA Approves Sanofi's Hemophilia Drug - Benzinga
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi - Morningstar
4 healthcare stocks attractive on valuation and ESG risk - Morningstar Australia
SNY Quantitative Stock Analysis - Nasdaq
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Know Labs Inc (KNW) Stock: A Closer Look at the Market Potential - The News Heater
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Piper Sandler Shows Market Leadership With Jump To 83 RS Rating - Inkl
Sanofi ADR Shows Market Leadership With Jump To 82 RS Rating - Investor's Business Daily
Gold Field ADR Sees Its Composite Rating Rise To 99 - Inkl
ZEEKR Intelligent ADR Shows Rising Price Performance With Jump To 80 RS Rating - Inkl
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
ESPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Investor's Business Daily
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Sanofi Reports Strong Q4 Sales Growth, Plans €5 Billion Buyback in 2025 - GuruFocus.com
Sanofi ADR earnings beat by $0.53, revenue fell short of estimates - Investing.com South Africa
Sanofi ADR (SNY) Recovers 15.33% From Low: Are We There Yet? - Stocks Register
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):